Evidence map›Paper›PMID 42782901›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Prognostic Implications of Recurrence Patterns and Time to Recurrence in Post-Hepatectomy Hepatocellular Carcinoma Recurrence: An Exploratory Analysis.

Jianwei Chen, Wenhao Teng, Mingji Zhang, Xiaolong Wang, Yuemin Zhu, Liting Wen, Juyi Wu, Dechun Zheng, Zhuting Fang

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jianwei ChenDepartment of Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.ORCID 0000-0002-5791-9865
Wenhao TengDepartment of Hepatopancreatobiliary Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Mingji ZhangDepartment of Hepatopancreatobiliary Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Xiaolong WangDepartment of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Yuemin ZhuDepartment of Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Liting WenDepartment of Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Juyi WuDepartment of Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Dechun ZhengDepartment of Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Zhuting FangDepartment of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.

Funding

Fujian Provincial Health Technology Project 2025QNB021Joint Funds for the Innovation of Science and Technology, Fujian province 2024Y9620
6 · The paper itself

Abstract

Post-recurrence survival (PRS) after hepatectomy for hepatocellular carcinoma (HCC) varies widely, yet the prognostic significance of the recurrence pattern and time to recurrence (TTR) for PRS remains incompletely defined. This single-center retrospective study included 126 patients with first HCC recurrence after curative hepatectomy (2018-2024) and aimed to explore the prognostic role of recurrence pattern, classified as low-risk (oligo-recurrence: ≤3 intrahepatic nodules, each ≤3 cm) or high-risk (multiple/large intrahepatic, tumor in vein, or extrahepatic), for PRS. In the overall cohort, the recurrence pattern independently predicted PRS (hazard ratio 2.13,

Indexed as

Carcinoma, HepatocellularHepatectomyLiver NeoplasmsNeoplasm Recurrence, LocalAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesBCLC stagehepatocellular carcinomapost-recurrence survivalrecurrence patterntime to recurrence

Identifiers

PMID42782901
PMCPMC13605822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.